Vertex Pharma (VRTX) Misses Q4 EPS by 5c; offers guidance
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $509.43 +0.21%
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: +10.7%
Financial Fact:
Loss from operations: -18.73M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $5.03, $0.05 worse than the analyst estimate of $5.08. Revenue for the quarter came in at $3.19 billion versus the consensus estimate of $3.18 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of $13.001 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
- HP Inc. projects mid-single-digit PC market decline in 2027
- Increasing unusual put option volume: AS NUAI NTSK INTW CMCSA BNY VUG NTRA WBD
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
